Amylyx Pharmaceuticals Inc. has entered into a collaboration with Gubra A/S to develop a novel long-acting GLP-1 receptor antagonist. This partnership involves Amylyx making upfront and research ...
Today, Gubra A/S ("Company"), a company specializing in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, announced a collaboration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback